Puma Biotechnology Inc

Puma Biotechnology Inc

NNASDAQ:PBYI
7.34
USD
-0.43
(-5.53%)
0.46EPS
21.22P/E
513.27MMarket Cap
Mar 04Next Earn

Total Valuation

USD

As of September 30, 2026, Puma Biotechnology Inc carries a market capitalization of 513.27M, placing it among publicly traded companies globally. Its enterprise value stands at 409.56M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap513.27M
Enterprise Value409.56M

Important Dates

Puma Biotechnology Inc's next confirmed earnings release is scheduled for March 4, 2027.

Earnings Date3/4/2027

Share Statistics

As of September 30, 2026, Puma Biotechnology Inc has 51.69M shares outstanding.

Shares Outstanding51.69M

Valuation Ratios

As of September 30, 2026, Puma Biotechnology Inc trades at a trailing price-to-earnings ratio of 21.22. The price-to-sales ratio is 2.18, and the price-to-book ratio stands at 3.50.

PE Ratio21.22
PS Ratio2.18
PB Ratio3.50
P/TBV Ratio4.56
P/FCF Ratio11.21
P/OCF Ratio10.99

Enterprise Valuation

As of September 30, 2026, Puma Biotechnology Inc trades at an EV/EBITDA multiple of 11.27 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.77 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 15.67 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Puma Biotechnology Inc trades at an EV/FCF ratio of 8.57, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 409.56M versus a market cap of 513.27M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.77
EV / EBITDA11.27
EV / EBIT15.67
EV / FCF8.57

Financial Position

As of September 30, 2026, Puma Biotechnology Inc maintains a current ratio of 3.03, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.32, indicating elevated leverage, while an interest coverage ratio of 17.90 demonstrates strong ability to service its debt obligations.

Current Ratio3.03
Quick Ratio2.72
Debt / Equity3.32
Debt / EBITDA0.13
Interest Coverage17.90

Financial Efficiency

USD

Over the twelve months ended September 30, 2026, Puma Biotechnology Inc posted a return on equity (ROE) of 18.20, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 14.40 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 11.75, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 16.60, useful for judging operating efficiency across full business cycles. The company generates approximately 1.30M in revenue per employee across its workforce of 179.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 5.84 indicates how many times Puma Biotechnology Inc sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)18.20
Return on Assets (ROA)11.75
Return on Invested Capital (ROIC)14.40
Return on Capital Employed (ROCE)16.60
Revenue Per Employee1.30M
Employee Count179.00
Inventory Turnover5.84

Taxes

USD

Over the twelve months ended September 30, 2026, Puma Biotechnology Inc recorded 4.27M in income tax expense. That works out to an effective tax rate of 15.19, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 28.10M, leaving 23.83M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax4.27M
Effective Tax Rate15.19

Stock Price Statistics

USD

As of the close on November 16, 2026, Puma Biotechnology Inc's stock has gained approximately 50.10% over the past 52 weeks. The 50-day moving average sits at 9.71, while the 200-day moving average is 8.04.

52-Week Price Change50.10%
50-Day Moving Average9.71
200-Day Moving Average8.04

Income Statement

USD

Over the twelve months ended September 30, 2026, Puma Biotechnology Inc generated 231.83M in revenue and converted that into 23.83M in net income, yielding earnings per share of 0.46. EBITDA reached 36.35M, while operating income came in at 26.14M.

Revenue231.83M
Gross Profit170.60M
Operating Income26.14M
Pretax Income28.10M
Net Income23.83M
EBITDA36.35M
EBIT26.14M
Earnings Per Share (EPS)0.46

Balance Sheet

USD

As of September 30, 2026, Puma Biotechnology Inc holds 108.58M in cash and equivalents against 4.87M in total debt, resulting in a net debt position of -41.55M. Total book value stands at 146.61M, with working capital of 105.66M providing operational flexibility.

Cash & Cash Equivalents108.58M
Total Debt4.87M
Net Debt-41.55M
Equity (Book Value)146.61M
Book Value Per Share2.84
Working Capital105.66M

Cash Flow

USD

Puma Biotechnology Inc produced 46.04M in operating cash flow over the twelve months ended September 30, 2026. After subtracting 36,000.00 in capital expenditures, free cash flow totaled 46.07M - equivalent to 0.90 per share.

Operating Cash Flow46.04M
Capital Expenditures36,000.00
Free Cash Flow46.07M
FCF Per Share0.90

Margins

Over the twelve months ended September 30, 2026, Puma Biotechnology Inc posted a gross margin of 73.59, reflecting its pricing power and cost economics. The operating margin of 11.27 and net profit margin of 10.28 provide insight into operational efficiency.

Gross Margin73.59
Operating Margin11.27
Pretax Margin12.12
Profit Margin10.28
EBITDA Margin15.68

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield stands at 8.92, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 6.60, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Puma Biotechnology Inc shareholders.

Shareholder Yield6.60
FCF Yield8.92

Scores

As of September 30, 2026, Puma Biotechnology Inc has an Altman Z-Score of -2.45, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-2.45